Radiopharm Theranostics Limited American
$3.55 -$0.74 (-17.25%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 27
Offering paper hit the record (Form 424B5).
424B5 - Radiopharm Theranostics Ltd (0001949257) (Filer)
RECEIPT: SEC FORM 424B5, TIMESTAMPED -
Jul 27
An insider transaction hit the record.
Form 4s are events, not verdicts — officers, directors, and 10% owners reporting their own trades. The forms post hours before the media writes them up.
RECEIPT: SEC FORM 4, TIMESTAMPED -
Jul 24
From its Feb 2 high, the share price fell 31%.
Peak close $5.15 on Feb 2; trough close $3.55 on Jul 24. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -31% -
Jul 24
The stock moved -17.2% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jul 24 -
Jul 23
Offering paper hit the record (Form 424B5).
424B5 - Radiopharm Theranostics Ltd (0001949257) (Filer)
RECEIPT: SEC FORM 424B5, TIMESTAMPED -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Mar 24
The stock moved -10.8% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 24
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Radiopharm Theranostics Limited American
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.